Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Gains from Investment Securities (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Gains from Investment Securities over the past 3 years, most recently at $65755.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $65755.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $65755.0 (changed N/A YoY), and the annual figure for FY2025 was $65755.0, up 1799.88%.
  • Gains from Investment Securities for Q4 2025 was $65755.0 at Tonix Pharmaceuticals Holding, down from $1.1 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for TNXP hit a ceiling of $5.8 million in Q1 2023 and a floor of -$7.0 million in Q1 2024.
  • Median Gains from Investment Securities over the past 3 years was $27509.0 (2023), compared with a mean of $160565.5.
  • Biggest five-year swings in Gains from Investment Securities: plummeted 220.68% in 2024 and later surged 4282.22% in 2025.
  • Tonix Pharmaceuticals Holding's Gains from Investment Securities stood at $774.0 in 2023, then soared by 3258.66% to $25996.0 in 2024, then skyrocketed by 152.94% to $65755.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $65755.0 (Q4 2025), $1.1 million (Q3 2025), and $35.0 (Q2 2025) per Business Quant data.